1 2 3 4 VOLUME 23 | NUMBER 10 | OCTOBER 2017 nature medicine Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival 1 . However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs) 2-4 . Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically 5,6 . Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner 7 , we searched for such vulnerabilities in CML LSCs. We performed metabolic analyses on both stem cell-enriched (CD34 + and CD34 + CD38 − ) and differentiated (CD34 − ) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts. Through combination of stable isotope-assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metabolism for their survival. We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML. Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival 1 . However, TKIs primarily target differentiated cells and do not eliminate leukemic stem cells (LSCs) [2] [3] [4] . Therefore, targeting minimal residual disease to prevent acquired resistance and/or disease relapse requires identification of new LSC-selective target(s) that can be exploited therapeutically 5, 6 . Considering that malignant transformation involves cellular metabolic changes, which may in turn render the transformed cells susceptible to specific assaults in a selective manner 7 , we searched for such vulnerabilities in CML LSCs. We performed metabolic analyses on both stem cell-enriched (CD34 + and CD34 + CD38 − ) and differentiated (CD34 − ) cells derived from individuals with CML, and we compared the signature of these cells with that of their normal counterparts. Through combination of stable isotope-assisted metabolomics with functional assays, we demonstrate that primitive CML cells rely on upregulated oxidative metabolism for their survival. We also show that combination treatment with imatinib and tigecycline, an antibiotic that inhibits mitochondrial protein translation, selectively eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML. Our findings provide a strong rationale for investigation of the use of TKIs in combination with tigecycline to treat patients with CML with minimal residual disease.
CML is a myeloproliferative disorder brought about by the chromosomal translocation t(9;22) (q34;q11) in a hematopoietic stem cell (HSC) 8, 9 that drives the expansion of a leukemic clone via expression of BCR-ABL, a chimeric oncoprotein with constitutive tyrosine kinase activity 10 . Prolonged treatment with TKIs to sustain remission is often associated with drug toxicity and/or acquired resistance and entails high monetary costs. On the other hand, rapid relapse is seen in half of patients after treatment discontinuation [11] [12] [13] . Therefore, to identify potential curative treatments that effectively eradicate CML LSCs, we specifically studied stem cell-enriched CD34 + cells derived from individuals with CML. In culture, proliferating untreated CD34 + primary CML cells rapidly lose surface CD34 expression ( Supplementary  Fig. 1a ). Imatinib treatment primarily targets differentiated CD34 − CML cells for apoptosis, leading to enrichment of more primitive CD34 + cells ( Supplementary Fig. 1a,b) . Consequently, imatinib decreases the efficiency with which primary CML progenitor cells form colonies in a short-term colony-forming cell (CFC) assay but, in line with the resistance of CML stem cells to TKI treatment, it does not affect the colony-forming capacity of CD34 + cells in a long-term culture initiating cell (LTC-IC) assay ( Supplementary Fig. 1c,d) .
As stem cells can exhibit different metabolic traits than their corresponding differentiated cells [14] [15] [16] , we metabolically profiled CD34 + and CD34 − CML cells derived from four individuals with CML by recording the steady-state levels of 70 metabolites central to glucose, nucleotide, amino acid, fatty acid and energy metabolism through liquid chromatography-mass spectrometry (LC-MS). The pattern of metabolite levels in the stem cell-enriched population, as compared to that in differentiated CML cells, revealed a potential increase in lipolysis and fatty acid oxidation; we found an increase in glycerol-3-phosphate, carnitine and acylcarnitine derivatives, as well as a decrease in free fatty acids, such as oleic and stearic acids ( Fig. 1a and Supplementary Table 1 ). Of note, fatty acid oxidation has been associated with the maintenance of HSCs and potentially with leukemogenesis 17, 18 . In order to validate and further substantiate these findings, leukemic cells were cultured for 24 h in the presence of uniformly labeled [ 13 C 16 ] palmitate and 13 C isotope enrichment in different palmitate-derived metabolites was measured by LC-MS. Substantial enhancement of palmitate-derived carbon in tricarboxylic acid (TCA) cycle metabolites and TCA cycle-derived amino acids was observed in CD34 + leukemic cells in comparison to differentiated CD34 − cells from the same individual ( Supplementary  Fig. 2a ). Furthermore, the steady-state levels of these metabolites were increased in stem cell-enriched CML cell populations whereas lactate levels were decreased relative to the differentiated CD34 − cells Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells ( Fig. 1a, Supplementary Fig. 2a and Supplementary Table 1 ). Steady-state levels of aspartate were recently recognized as a bona fide indicator of mitochondrial oxidative capacity [19] [20] [21] . Accordingly, CML cells derived from the four individuals with CML presented on average a 3.0-fold increase in the mitochondrial oxygen consumption rate (OCR) in CD34 + cells as compared to subject-matched CD34 − cells. Moreover, the strong decrease in oxygen consumption upon inhibition of ATP synthase with oligomycin demonstrated that the increased oxygen consumption is tightly linked to ATP production in these cells (Fig. 1b,c) . However, the increase in steady-state levels of TCA cycle metabolites and derived amino acids could not be solely explained by an increase in fatty acid oxidation, as the production of acetyl-coenzyme A (CoA) from palmitate does not support net production of TCA cycle metabolites (anaplerosis).
To study oxidative metabolism and anaplerosis in more detail, glucose, an anaplerosis-enabling metabolite, was traced in leukemic cells cultured for 24 h with uniformly labeled [ 13 C 6 ]glucose. In this analysis, TCA cycle metabolites from CD34 + CML cells contained a significantly larger fraction of isotopologs with two, three or more 13 C atoms than metabolites from CD34 − cells (Fig. 1d) . The larger fractions of labeled TCA cycle-derived glutamate and aspartate observed in CD34 + CML cells confirmed the higher oxidative and anaplerotic activity in these cells. Concurrently, CD34 + cells demonstrated a noticeable (although not significant) decrease in glucose-derived lactate ([ 13 C 3 ]lactate), indicating that pyruvate is indeed more effectively shunted toward the TCA cycle in these cells ( Fig. 1d) . Increased levels of acetyl-CoA produced from fatty acid oxidation are predicted to increase the anaplerotic activity of pyruvate carboxylase (PC) but potentially to inhibit pyruvate dehydrogenase (PDH) activity. We therefore estimated the relative metabolic contributions of these enzymes in [ relevant product ([ 13 C 3 ]aspartate for PC and [ 13 C 2 ]citrate for PDH). Although no difference in PDH activity was detected between the two subsets of CML cells, the relative activity of PC was significantly higher in CD34 + CML cells, further confirming their increased oxidative anaplerotic metabolism (Supplementary Fig. 2b,c) .
To investigate whether this oxidative phenotype is unique to primitive CML cells, we assessed the metabolic profile of CD34 + cells from four individuals with CML and compared these with profiles of normal hematopoietic CD34 + cells from four donors. Higher steady-state levels of carnitine and acylcarnitine derivatives and lower levels of free fatty acids, such as oleic and linolenic acids, were detected in the CD34 + CML cells as compared to the normal cells ( Supplementary Fig. 3a and Supplementary Table 2 ). In line with this, the 13 CD34 + cells, demonstrating that the increase in fatty acid oxidation observed previously is specific to CD34 + CML cells ( Supplementary  Fig. 3b-d) . Following incubation with [ 13 C 6 ]glucose, the enrichment of glucose-derived 13 C isotopes in citrate, glutamate and aspartate was significantly higher in CD34 + CML cells than in their normal counterparts. This finding, in combination with a significant increase in the relative activity of both PC and PDH, demonstrates a selective increase in glucose oxidation and anaplerosis in leukemic cells ( Fig. 2a-c and Supplementary Fig. 3e,f) . Moreover, the mitochondrial respiration of leukemic CD34 + samples was on average 3.3-fold higher than that of normal CD34 + cells ( Fig. 2d,e ). As pools of CD34 + cells contain both stem and progenitor cells, we next verified our findings in a population of CD34 + CD38 − CML cells; this is a rare quiescent subpopulation (~5% of total CD34 + cells) that is further enriched for LSCs. Flow cytometry analysis of mitochondrial content and mitochondrial membrane potential suggested that CML LSCs possess increased mitochondrial oxidative functions as compared to normal HSCs ( Fig. 2f-i) . Moreover, CD34 + CD38 − cells isolated from two individuals with CML that were incubated with [ 13 C 6 ]glucose contained increased levels of 13 C isotopologs for citrate, aspartate and glutamate as compared to normal CD34 + CD38 − cells, confirming that CML LSCs have increased oxidative metabolism ( Fig. 2j-l and Supplementary Fig. 3g-i) .
These findings suggest that, in primitive CML cells, mitochondrial oxidative metabolism is crucial for production of energy and anabolic precursors and that restraining mitochondrial functions may have a therapeutic benefit. Tigecycline is a US Food & Drug Administration (FDA)-approved antibiotic that inhibits bacterial protein synthesis. Because of the similarity of mitochondrial and bacterial ribosomes, it also inhibits the synthesis of mitochondrion-encoded proteins, all of which are required for the oxidative phosphorylation machinery 22 . Previous reports demonstrated therapeutic efficacy of tigecycline against cancer cells, including primary acute myeloid leukemia cells 23 and the oxidative subtype of diffuse large B cell lymphoma 22 . First, we demonstrated that tigecycline was capable of inhibiting translation of the mitochondrially encoded proteins cytochrome c oxidase I (MT-CO1) and MT-CO2, but not the nuclear-encoded mitochondrial proteins ATP5A and ubiquinol-cytochrome c reductase core protein l e t t e r s II (UQCRC2) ( Fig. 3a and Supplementary Fig. 4a ). This was associated with a compensatory increase in MT-CO1 and MT-CO2 mRNA levels (Supplementary Fig. 4b ). In line with this observation, tigecycline treatment significantly impaired mitochondrial respiration in CD34 + CML cells (Supplementary Fig. 4c ). Primary CD34 + CML cells were then cultured with [ 13 C 6 ]glucose for 24 h in the presence or absence of tigecycline. A robust and significant decrease in glucose oxidation was noted in tigecycline-treated cells, with a 2.8-to 3.4-fold decrease in the incorporation of 13 C isotopes into citrate, glutamate and aspartate ( Fig. 3b-d) . Tigecycline had a broad effect on cellular metabolism, as illustrated by a combined decrease in respiration and extracellular acidification rate ( Supplementary Fig. 4c,d) , which is indicative of concurrent impairment of oxidative phosphorylation and glycolysis. This phenotype was associated with a decrease in the relative activity of both PDH and PC (Supplementary Fig. 4e,f) . Similarly, CD34 + CML cells treated with tigecycline displayed a significant decrease in the fraction of isotopologs with two or more 13 C atoms following incubation with [ 13 C 5 ]glutamine and [ 13 C 16 ]palmitate (Supplementary Fig. 4g-l) . In tandem with blocking oxidative metabolism, tigecycline treatment decreased the overall steady-state levels of aspartate (Fig. 3d) , which supports the anaplerotic role of oxidative metabolism in the LSC-enriched population.
Oxidative phosphorylation and anaplerosis are essential for cell growth and proliferation. In experiments in which CD34 + CML cells were labeled with a fluorescent tracker of cell division, tigecycline alone or in combination with imatinib strongly impaired the proliferation of primary CD34 + CML cells whereas imatinib alone had only a moderate effect, in line with the preferential effect of imatinib on differentiated CD34 − cells (Fig. 3e) . Furthermore, treatment with imatinib or tigecycline alone decreased the number of shortterm CML CFCs and combined application of these drugs effectively eliminated colony formation ( Fig. 3f,g) . This effect on colony growth correlated with an increase in cell death as measured by Annexin V staining ( Supplementary Fig. 5a,b) . Notably, neither drug, alone or in combination, had a significant effect on normal, nonleukemic CFCs, affirming a potential therapeutic window (range of doses that produce therapeutic response without substantial toxicity; Fig. 3h ). Thus far, our studies suggest that the combined inhibitory effect of tigecycline and imatinib on CFCs may result from the effects of the drugs on two distinct cell populations: imatinib targets more mature progenitors, while tigecycline targets the more oxidative, long-term LSCs. To test this hypothesis, an LTC-IC assay was performed in which CD34 + CML cells were treated once with imatinib or tigecycline, alone or in combination, followed by liquid culture for 5 weeks before placement in semisolid medium. This method ensures selective measurement of the functional capacity of long-term LSCs, as short-term progenitor cells lose their colony-forming potential during the 5 weeks in liquid culture. This stringent in vitro stem cell assay revealed that, while imatinib was ineffective, tigecycline-mediated inhibition of oxidative metabolism significantly decreased CML LSC potential (Fig. 3i) . Similar findings were observed when the mitochondrial complex I inhibitor phenformin was used ( Supplementary Fig. 5c,d) .
To further assess the clinical relevance of these findings, we moved to a robust xenotransplantation model of human CML. Sublethally irradiated immunocompromised mice were transplanted with CD34 + human CML cells. Six weeks following transplantation, engraftment was assessed by recording the percentage of cells expressing human CD45 among the total peripheral leukocytes in the blood (Fig. 4a) . Fig. 6a) , we treated the mice daily starting at 6 weeks after transplantation for a period of 4 weeks with vehicle only, tigecycline (escalating doses of 25-100 mg per kg body weight; Online Methods), imatinib (100 mg per kg body weight) or both drugs in combination (Fig. 4a) . In all experimental arms, no changes in body or spleen weight or signs of toxicity were observed during treatment and total bone marrow cellularity was unaffected, confirming excellent tolerability (Supplementary Fig. 6b-d) . Decreased levels of mitochondrion-encoded proteins were used as a pharmacodynamic biomarker to demonstrate on-target action of tigecycline in vivo (Supplementary Fig. 6e ). Following treatment, bone marrow cells were extracted and analyzed by flow cytometry for expression of the human antigens CD45 (on leukocytes), CD34 (on progenitors and stem cells) and CD38 (to distinguish between CD34 + CD38 + progenitors and CD34 + CD38 − LSCs). The majority of bone marrow cells were nonleukemic host cells (human CD45 − ) and, as indicated above, were unaffected by treatment compared to vehicle-treated mice ( Fig. 4b and Supplementary  Fig. 7a) . In contrast, the total number of CML-derived CD45 + cells in the bone marrow was decreased marginally in tigecycline-treated mice and significantly in imatinib-treated mice compared to vehicle-treated mice (Supplementary Fig. 7b) . Notably, the CML burden was further decreased in the arm with combined treatment, and when only undifferentiated CD45 + CD34 + CML cells from the bone marrow were analyzed this result was even more pronounced (Fig. 4b,c and Supplementary Fig. 7a,b) . However, the most striking effect was seen within the more primitive population of human LSCs. Whereas imatinib alone only marginally (and not significantly) decreased the number of CD45 + CD34 + CD38 − CML cells, combination treatment eliminated 95% of these cells (Fig. 4d) .
After ensuring equivalent and sufficient engraftment of human cells in all mice (Supplementary
Experiments using cord blood CD34 + cells showed that both imatinib and tigecycline, alone or in combination, had a marginal effect on engrafted normal blood cells (Supplementary Fig. 8a-c) . Finally, an additional two cohorts of mice received transplants of CD34 + CML cells and were treated as described above. To investigate whether the combination of tigecycline and imatinib slowed the rate of relapse, both cohorts were then left untreated for an additional 2 weeks (experiment 1) or 3 weeks (experiment 2). Bone marrow analysis following drug withdrawal demonstrated that, while mice treated with imatinib as a single agent showed signs of relapse (with the number of leukemic cells similar to that in untreated mice), the vast majority of mice treated with the combination of tigecycline and imatinib sustained low numbers of LSCs in the bone marrow (Fig. 4e,f) .
Taken together, our findings indicate that primitive CML stem and progenitor cells are highly susceptible to inhibition of oxidative phosphorylation, whereas normal CD34 + cells are not. This previously unknown metabolic vulnerability shown here represents a therapeutic target for treatment with the FDA-approved mitochondrial translation inhibitor tigecycline. Finally, combining tigecycline treatment with the standard-of-care drug imatinib in vivo produces a selective cytotoxic effect on CD34 + CML cells and on more primitive LSCs at clinically administrable doses.
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ONLINe MeTHODS
Reagents. Imatinib mesylate was purchased from LC Laboratories. Stock solution of 1 mM imatinib was prepared in sterile distilled water and stored at 4 °C. Tigecycline powder (catalog no. T3324-1, LKT Laboratories) was stored at 4 °C and 5 mM solutions were freshly prepared in DMSO (Sigma-Aldrich) on the day of the experiment. Cell culture. Primary samples were cultured at 37 °C and 5% CO 2 in serumfree medium (SFM) consisting of Iscove's modified Dulbecco medium (Sigma-Aldrich) supplemented with bovine serum albumin (BSA), insulin and transferrin (BIT9500, StemCell Technologies), 1 mM penicillinstreptomycin, 0.1 mM 2-mercaptoethanol, and a physiological growth factor (PGF) cocktail comprising 0.2 ng/ml stem cell factor (SCF), granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage inflammatory protein (MIP)-α, 1.0 ng/ml granulocyte colony-stimulating factor (G-CSF) and interleukin (IL)-6 (PeproTech EC) and 0.05 ng/ml leukemia inhibitory factor (LIF) (StemCell Technologies).
Drug treatment.
Imatinib, tigecycline and phenformin in vitro treatments were performed at a concentration of 2 µM, 2.5 µM and 20 µM, respectively, unless stated otherwise.
Oxygen consumption rate measurements. OCR was measured using the Seahorse XF96 analyzer (Seahorse Bioscience, Billerica, MD). Primary cells were suspended in XF Assay Medium supplemented with 25 mM glucose, 1 mM pyruvate and PGF cocktail. 60,000-100,000 cells were seeded per well of a Seahorse XF96 cell culture plate (35-µl volume) precoated with Cell-Tak (Fisher Scientific). Cells were left to adhere for a minimum of 30 min in a CO 2free incubator at 37 °C, after which 140 µl of XF Assay Medium was added into each well. The plate was left to equilibrate for 10 min in the CO 2 -free incubator before being transferred to the Seahorse XF96 analyzer. Measurement of OCR was done at baseline and following sequential injections of (i) oligomycin (1 µM), an ATP synthase inhibitor, (ii) carbonyl cyanide-4-(trifluorometh oxy)phenylhydrazone (FCCP) (1.6 µM), a mitochondrial uncoupler, and (iii) antimycin A (1 µM) and rotenone (1 µM; all Sigma-Aldrich), complex III and complex I inhibitors, respectively. This enabled us to measure the OCR coupled to ATP production (by subtracting the oligomycin rate from the baseline OCR), as well as the maximal OCR (by subtracting non-mitochondrial respiration (antimycin A and rotenone rate) from the FCCP rate) and the mitochondrial OCR (by subtracting non-mitochondrial respiration from the basal OCR) OCRs were normalized by cell number.
Cellular division tracking. CD34 + CML cells were stained with 1 µM
CellTrace Violet (CellTrace Violet Cell Proliferation Kit, Life Technologies) for 30 min at 37 °C. The reaction was quenched by adding cell culture medium containing 10% FBS. Cells were then suspended in SFM supplemented with PGF cocktail and treated (by subtracting the oligomycin rate from the baseline OCR) with tigecycline (2.5 µM) and imatinib (2 µM) as indicated. After 3 d, CellTrace Violet staining was assessed by flow cytometry (BD FACSVerse).
Colony-forming cell assay. Primary cells were plated in SFM supplemented with PGF cocktail in the presence of the indicated drugs. After 3 d, cells from each condition were transferred to methylcellulose-based medium (Methocult H4034 Optimum, StemCell Technologies) in duplicate, and colonies were manually counted after 12-14 d.
Human long-term culture initiating cell assay. CD34 + CML cells were plated onto irradiated stromal layers (M2-10B4 and S1/S1) in the presence of the indicated drugs in medium for long-term culture of human cells (MyeloCult H5100, StemCell Technologies). Cells were kept for a minimum of 5 weeks with a weekly half-medium change. At this point, the remaining viable progenitors were assessed by CFC assay.
Mitochondrial content and membrane potential. Mitochondrial content was assessed by co-staining CML and normal CD34 + cells with 100 nM MitoTracker Green (MTG; Thermo Fisher Scientific) with anti-human CD34 (APC) and anti-human CD38 (PerCP) antibodies for 30 min at room temperature. For assessments of mitochondrial membrane potential, cells were stained with 100 nM tetramethylrhodamine, methyl ester (TMRM; Thermo Fisher Scientific) and with anti-human CD34 (APC) and anti-human CD38 (PerCP) antibodies. Fluorescence levels following cellular staining were analyzed by flow cytometry.
Western blot analysis. CD34 + CML cells were lysed in RIPA buffer, and total protein concentration was measured with a Pierce BCA kit (Thermo Fisher Scientific). Equal amounts of protein (5-20 µg) were heated at 95 °C for 5 min and separated in 10% gels for SDS-PAGE. Proteins were transferred onto nitrocellulose membranes (Millipore), blocked in 5% BSA (in Tris-buffered saline (TBS) + 0.01% Tween) and incubated overnight at 4 °C with the following primary antibodies: total OXPHOS cocktail (Abcam, ab110413, 1:2,000) and MT-CO2 (Thermo Fisher Scientific, A-6404, 1:2,000). The membranes were then incubated with secondary HRP-linked antibodies (1:5,000) for 1 h at room temperature. The Pierce enhanced chemiluminescence detection system was used (Thermo Fisher Scientific).
Cell death. CD34 + CML cells were seeded at 2 × 10 5 cells/ml and treated for 72 h with 2.5 µM tigecycline, 2 µM imatinib or a combination of these drugs as indicated. Cell death was quantified by measuring the percentage of Annexin V (fluorescein isothiocyanate (FITC); BioLegend)-positive CD34 + CML cells by flow cytometry (BD FACSVerse).
RT-qPCR. CD34 + CML cells were seeded at 2 × 10 5 cells/ml and treated for 72 h with 2.5 µM tigecycline. RNA was extracted using the RNeasy Mini Kit (Qiagen). Reverse transcription was performed with SuperScript VILO Master Mix (Thermo Fisher Scientific).
The following primers were used: MT-CO1_F 5′-CTTTTCACCGTAGGTG GCCT-3′, MT-CO1_R 5′-AGTGGAAGTGGGCTACAACG-3′, MT-CO2_F 5′-CCGTCTGAACTATCCTGCCC-3′, MT-CO2_R 5′-GAGGGATCGTTGACCT CGTC-3′, 18S_F 5′-GTAACCCGTTGAACCCCATT-3′ and 18S_R 5′-CCATCCA ATCGGTAGTAGCG-3′. cDNAs were mixed with Fast SYBR Green Master Mix (4385612, Applied Biosystems) and 0.25 µM of each primer, and the volume was adjusted to 20 µl according to the manufacturer's instructions. PCR was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems) with the following steps: 20 s at 95 °C followed by 40 cycles of 3 s at 95 °C and 30 s at 60 °C. Relative quantification of mRNA was performed by the comparative ∆∆Ct method using 18S for normalization. Intracellular metabolite extraction. Primary cells were plated in the presence of [ 13 C 6 ]glucose, [ 13 C 5 ]glutamine or [ 13 C 16 ]palmitate for 24 h at a concentration of 0.5 × 10 6 cells/ml in custom-formulated serum-like culture medium containing physiological concentrations of metabolites found in human plasma. After 24 h, cells were washed twice with ice-cold PBS, and intracellular metabolites were extracted with a cold solution of methanol, acetonitrile and water (5:3:2). The cell extracts were centrifuged at 16,000g for 10 min at 4 °C, and the supernatants were subjected to LC-MS analysis.
Liquid chromatography-mass spectrometry analysis. LC analysis was performed as described previously 24, 25 . A Q-Exactive Orbitrap Mass Spectrometer (Thermo Scientific) was used together with a Thermo Scientific UltiMate 3000 HPLC system. The HPLC setup consisted of a ZIC-pHILIC column (SeQuant, 150 × 2.1 mm, 5 µm, Merck KGaA) with a ZIC-pHILIC guard column (SeQuant, 20 × 2.1 mm). The aqueous mobile-phase solvent was 20 mM ammonium carbonate plus 0.1% ammonium hydroxide solution and the organic mobile phase was acetonitrile. The metabolites were separated over a linear gradient from 80% organic to 80% aqueous for 15 min. The column temperature was 45 °C and the flow rate was 200 µl/min. The run time was 22.2 min. All metabolites were detected across a mass range of 75-1,000 m/z using the Q-Exactive mass spectrometer at a resolution of 35,000 (at 200 m/z) with electrospray ionization and polarity switching mode. Lock masses were used, and the mass accuracy obtained for all metabolites was below 5 p.p.m. Data were acquired with Thermo Xcalibur software.
The peak areas of different metabolites were determined using Thermo LCquan software through which metabolites were identified by the exact mass of the singly charged ion and by known retention time on the HPLC column. Commercially available standard compounds had been analyzed previously to determine ion masses and retention times on the ZIC-pHILIC column. The 13 C labeling patterns were determined by measuring peak areas for the accurate mass of each isotopolog of metabolites. Intracellular metabolites were normalized to cell number and volume.
Mouse engraftment.
To study the in vivo engraftment of CD34 + CML cells, 1.5 × 10 6 CD34 + CML cells were transplanted via tail vein into sublethally irradiated (2.5 Gy) female NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ NSG mice aged 8 weeks (Jackson Laboratory). Six weeks following transplant, drug treatment was started with imatinib (100 mg per kg body weight; oral gavage twice daily) and tigecycline for 4 weeks (week 1: 25 mg per kg body weight, week 2: 50 mg per kg body weight, weeks 3 and 4: 100 mg per kg body weight; intraperitoneal once daily). At the endpoint, bone marrow cells were stained with anti-human CD45 (FITC; BD Biosciences), anti-human CD34 (APC; BD Biosciences) and anti-human CD38 (PerCP; BioLegend) antibodies for flow cytometry analysis. Dual-fusion interphase fluorescence in situ hybridization (D-FISH) was performed as previously described 6 to verify engraftment of Ph + cells. To study the in vivo engraftment of normal cells, 1 × 10 5 cord blood CD34 + cells were transplanted into sublethally irradiated (2.5 Gy) female NSG mice aged 8 weeks (Jackson Laboratory). Six weeks following transplant, drug treatment was initiated using the same treatment schedule and dose as for CD34 + CML cells (see above). At the endpoint, the remaining cells were stained with anti-human CD45 (FITC; BD Biosciences), anti-human CD34 (APC; BD Biosciences) and anti-human CD38 (PerCP; BioLegend) antibodies and analyzed by flow cytometry.
For the drug-withdrawal experiments, 1 × 10 6 CD34 + CML cells were transplanted via tail vein into sublethally irradiated (2.5 Gy) female NSG mice aged 8-10 weeks (Jackson Laboratory). 6-8 weeks following transplant, mice were treated with imatinib (100 mg per kg body weight; oral gavage twice daily) and tigecycline (intraperitoneal once daily) for an additional 3 to 4 weeks (experiment 1: week 1, 25 mg per kg body weight; week 2, 50 mg per kg body weight; weeks 3 and 4, 100 mg per kg body weight; experiment 2: week 1, 25 mg per kg body weight; week 2, 50 mg per kg body weight; week 3, 100 mg per kg body weight). Mice were then left untreated for an additional 2 (experiment 1) or 3 (experiment 2) weeks. At the endpoint, bone marrow cells were stained with anti-human CD45 (FITC; BD Biosciences), anti-human CD34 (APC; BD Biosciences) and antihuman CD38 (PerCP; BioLegend) antibodies for flow cytometry analysis.
Ethics. Ethical approval has been given to the research tissue bank (REC 15/WS/0077) and for use of surplus human tissue in research (REC 10/S0704/60). Animal work was carried out with ethical approval from the University of Glasgow Animal Welfare and Ethical Review Board (AWERB) under the Animal (Scientific Procedures) Act of 1986.
Statistical analyses.
No statistical method was used to predetermine sample size. For in vitro experiments, a minimum of three samples was chosen as a sample size to ensure adequate power. Data obtained from each sample represent an independent experiment. For in vivo work, a minimum of two mice per treatment arm were used. The investigators were not blinded to allocation during experiments. Mice were allocated on the basis of their pretreatment engraftment levels, and no method of randomization was used. All mice were cared for equally in an unbiased fashion by animal technicians and investigators. No animal was excluded from the analysis. P values were calculated by two-tailed paired or unpaired Student's t-test using GraphPad Prism software (GraphPad Software 5.0), as indicated in the figure legends. Where indicated, variables were transformed using the natural logarithms before t-tests were performed to meet the assumption of equal variances. Data availability. Data from this study are available upon reasonable request. Additional information regarding human samples is available from the corresponding author upon reasonable request. Additional information regarding human samples, experimental design and materials can be found in the Life Sciences Reporting Summary.
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Data exclusions
Describe any data exclusions. For in vitro LTC-IC experiments, 2 patients were excluded from the analysis as no visible colonies were present in the vehicle-treated condition following 5-week in vitro culture. For in vivo experiments, no animal was excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
Each experiment was reproduced at least 3 times independently (unless otherwise stated) and were reproducible.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Primary human samples or animals were not randomized. For in vitro work primary samples were selected by disease stage (i.e. CML chronic phase). For in vivo work, primary samples were selected by transplantability into NSG mice. Prior to drug treatment, mice were allocated based on their pre-treatment engraftment levels.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Statistic analysis: GraphPad Prism 5.03
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
CML and normal samples required informed consent in accordance with the Declaration of Helsinki and approval of the National Health Service (NHS) Greater Glasgow Institutional Review Board. Ethical approval has been given to the research tissue bank (REC 15/WS/0077) and for using surplus human tissue in research (REC 10/S0704/60).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Total OXPHOS cocktail (Abcam, ab110413) and MT-CO2 (Thermo Fisher Scientific, A-6404) were both validated to react with human by the suppliers. 
